Rumbold Alice, Ota Erika, Nagata Chie, Shahrook Sadequa, Crowther Caroline A
The Robinson Research Institute, The University of Adelaide, Ground Floor, Norwich Centre, 55 King William Road, Adelaide, NT, Australia, SA 5006.
Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD004072. doi: 10.1002/14651858.CD004072.pub3.
Vitamin C supplementation may help reduce the risk of pregnancy complications such as pre-eclampsia, intrauterine growth restriction and maternal anaemia. There is a need to evaluate the efficacy and safety of vitamin C supplementation in pregnancy.
To evaluate the effects of vitamin C supplementation, alone or in combination with other separate supplements on pregnancy outcomes, adverse events, side effects and use of health resources.
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 March 2015) and reference lists of retrieved studies.
All randomised or quasi-randomised controlled trials evaluating vitamin C supplementation in pregnant women. Interventions using a multivitamin supplement containing vitamin C or where the primary supplement was iron were excluded.
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy.
Twenty-nine trials involving 24,300 women are included in this review. Overall, 11 trials were judged to be of low risk of bias, eight were high risk of bias and for 10 trials it was unclear. No clear differences were seen between women supplemented with vitamin C alone or in combination with other supplements compared with placebo or no control for the risk of stillbirth (risk ratio (RR) 1.15, 95% confidence intervals (CI) 0.89 to 1.49; 20,038 participants; 11 studies; I² = 0%; moderate quality evidence), neonatal death (RR 0.79, 95% CI 0.58 to 1.08; 19,575 participants; 11 studies; I² = 0%), perinatal death (average RR 1.07, 95% CI 0.77 to 1.49; 17,105 participants; seven studies; I² = 35%), birthweight (mean difference (MD) 26.88 g, 95% CI -18.81 to 72.58; 17,326 participants; 13 studies; I² = 69%), intrauterine growth restriction (RR 0.98, 95% CI 0.91 to 1.06; 20,361 participants; 12 studies; I² = 15%; high quality evidence), preterm birth (average RR 0.99, 95% CI 0.90 to 1.10; 22,250 participants; 16 studies; I² = 49%; high quality evidence), preterm PROM (prelabour rupture of membranes) (average RR 0.98, 95% CI 0.70 to 1.36; 16,825 participants; 10 studies; I² = 70%; low quality evidence), term PROM (average RR 1.26, 95% CI 0.62 to 2.56; 2674 participants; three studies; I² = 87%), and clinical pre-eclampsia (average RR 0.92, 95% CI 0.80 to 1.05; 21,956 participants; 16 studies; I² = 41%; high quality evidence).Women supplemented with vitamin C alone or in combination with other supplements compared with placebo or no control were at decreased risk of having a placental abruption (RR 0.64, 95% CI 0.44 to 0.92; 15,755 participants; eight studies; I² = 0%; high quality evidence) and had a small increase in gestational age at birth (MD 0.31, 95% CI 0.01 to 0.61; 14,062 participants; nine studies; I² = 65%), however they were also more likely to self-report abdominal pain (RR 1.66, 95% CI 1.16 to 2.37; 1877 participants; one study). In the subgroup analyses based on the type of supplement, vitamin C supplementation alone was associated with a reduced risk of preterm PROM (average RR 0.66, 95% CI 0.48 to 0.91; 1282 participants; five studies; I² = 0%) and term PROM (average RR 0.55, 95% CI 0.32 to 0.94; 170 participants; one study). Conversely, the risk of term PROM was increased when supplementation included vitamin C and vitamin E (average RR 1.73, 95% CI 1.34 to 2.23; 3060 participants; two studies; I² = 0%). There were no differences in the effects of vitamin C on other outcomes in the subgroup analyses examining the type of supplement. There were no differing patterns in other subgroups of women based on underlying risk of pregnancy complications, timing of commencement of supplementation or dietary intake of vitamin C prior to trial entry. The GRADE quality of the evidence was high for intrauterine growth restriction, preterm birth, and placental abruption, moderate for stillbirth and clinical pre-eclampsia, low for preterm PROM.
AUTHORS' CONCLUSIONS: The data do not support routine vitamin C supplementation alone or in combination with other supplements for the prevention of fetal or neonatal death, poor fetal growth, preterm birth or pre-eclampsia. Further research is required to elucidate the possible role of vitamin C in the prevention of placental abruption and prelabour rupture of membranes. There was no convincing evidence that vitamin C supplementation alone or in combination with other supplements results in other important benefits or harms.
补充维生素C可能有助于降低先兆子痫、胎儿生长受限和孕妇贫血等妊娠并发症的风险。有必要评估孕期补充维生素C的疗效和安全性。
评估单独补充维生素C或与其他单独补充剂联合使用对妊娠结局、不良事件、副作用及卫生资源利用的影响。
我们检索了Cochrane妊娠与分娩组试验注册库(2015年3月31日)以及检索到的研究的参考文献列表。
所有评估孕妇补充维生素C的随机或半随机对照试验。排除使用含维生素C的多种维生素补充剂或主要补充剂为铁剂的干预措施。
两位综述作者独立评估试验是否纳入及偏倚风险,提取数据并检查其准确性。
本综述纳入了29项涉及24300名女性的试验。总体而言,11项试验被判定为低偏倚风险,8项为高偏倚风险,10项试验情况不明。单独补充维生素C或与其他补充剂联合补充的女性与安慰剂组或无对照相比,在死产风险(风险比(RR)1.15,95%置信区间(CI)0.89至1.49;20038名参与者;11项研究;I² = 0%;中等质量证据)、新生儿死亡(RR 0.79,95%CI 0.58至1.08;19575名参与者;11项研究;I² = 0%)、围产期死亡(平均RR 1.07,95%CI 0.77至1.49;17105名参与者;7项研究;I² = 35%)、出生体重(平均差(MD)26.88 g,95%CI -18.81至72.58;17326名参与者;13项研究;I² = 69%)、胎儿生长受限(RR 0.98,95%CI 0.91至1.06;20361名参与者;12项研究;I² = 15%;高质量证据)、早产(平均RR 0.99,95%CI 0.90至1.10;22250名参与者;16项研究;I² = 49%;高质量证据)、早产胎膜早破(RR 0.98,95%CI 0.70至1.36;16825名参与者;10项研究;I² = 70%;低质量证据)、足月胎膜早破(平均RR 1.26,95%CI 0.62至2.56;2674名参与者;3项研究;I² = 87%)以及临床先兆子痫(平均RR 0.92,95%CI 0.80至1.05;21956名参与者;16项研究;I² = 41%;高质量证据)方面未观察到明显差异。单独补充维生素C或与其他补充剂联合补充的女性与安慰剂组或无对照相比,胎盘早剥风险降低(RR 0.64,95%CI 0.44至0.92;15755名参与者;8项研究;I² = 0%;高质量证据),出生孕周略有增加(MD 0.31,95%CI 0.01至0.61;14062名参与者;9项研究;I² = 65%),然而她们也更有可能自我报告腹痛(RR 1.66,95%CI 1.16至2.37;1877名参与者;1项研究)。在基于补充剂类型的亚组分析中,单独补充维生素C与早产胎膜早破风险降低相关(平均RR 0.66, 95%CI 0.48至0.91;1282名参与者;5项研究;I² = 0%)以及足月胎膜早破风险降低相关(平均RR 0.55, 95%CI 0.32至0.94;170名参与者;1项研究)。相反,当补充剂包含维生素C和维生素E时,足月胎膜早破风险增加(平均RR 1.73, 95%CI 1.34至2.23;3060名参与者;2项研究;I² = 丝0%)。在检查补充剂类型的亚组分析中,维生素C对其他结局的影响无差异。在基于妊娠并发症潜在风险、补充开始时间或试验入组前维生素C饮食摄入量的其他女性亚组中,未发现不同模式。对于胎儿生长受限、早产和胎盘早剥,证据的GRADE质量为高,对于死产和临床先兆子痫为中等,对于早产胎膜早破为低。
数据不支持单独或与其他补充剂联合常规补充维生素C来预防胎儿或新生儿死亡、胎儿生长不良、早产或先兆子痫。需要进一步研究以阐明维生素C在预防胎盘早剥和胎膜早破中的可能作用。没有令人信服的证据表明单独或与其他补充剂联合补充维生素C会带来其他重要益处或危害。